Effect of Lanthanum Carbonate on All-Cause Mortality in Patients Receiving Maintenance Hemodialysis: a Meta-Analysis of Randomized Controlled Trials

Background/Aims: Hyperphosphatemia is common in patients on hemodialysis. The efficacy of lanthanum carbonate (LC) in the treatment of hyperphosphatemia in these patients remains controversial. The objective of this meta-analysis was to evaluate the effect of LC on all-cause mortality in patients on...

Full description

Saved in:
Bibliographic Details
Main Authors: Fang Wang (Author), Xiangxue  Lu (Author), Jingli Zhang (Author), Ruifang Xiong (Author), Han Li (Author), Shixiang Wang (Author)
Format: Book
Published: Karger Publishers, 2018-03-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_fa2f3fef4ca64aa7a84f2283594c55a5
042 |a dc 
100 1 0 |a Fang Wang  |e author 
700 1 0 |a Xiangxue  Lu  |e author 
700 1 0 |a Jingli Zhang  |e author 
700 1 0 |a Ruifang Xiong  |e author 
700 1 0 |a Han Li  |e author 
700 1 0 |a Shixiang Wang  |e author 
245 0 0 |a Effect of Lanthanum Carbonate on All-Cause Mortality in Patients Receiving Maintenance Hemodialysis: a Meta-Analysis of Randomized Controlled Trials 
260 |b Karger Publishers,   |c 2018-03-01T00:00:00Z. 
500 |a 1420-4096 
500 |a 1423-0143 
500 |a 10.1159/000488700 
520 |a Background/Aims: Hyperphosphatemia is common in patients on hemodialysis. The efficacy of lanthanum carbonate (LC) in the treatment of hyperphosphatemia in these patients remains controversial. The objective of this meta-analysis was to evaluate the effect of LC on all-cause mortality in patients on maintenance hemodialysis. Methods: We electronically searched the PubMed, EMBASE, and Cochrane Library databases for all randomized controlled trials (RCTs) comparing LC with other phosphate binders used in adult hemodialysis patients, including calcium carbonate, calcium acetate, and sevelamer. Results: Nine RCTs involving 2813 patients were suitable for inclusion. Our results showed that all-cause mortality was significantly lower in patients who received LC than in those who received standard therapy (odds ratio [OR]: 0.45, 95% confidence interval [CI]: 0.32-0.63, P<0.00001). Compared with the controls, patients who received LC had significantly lower serum calcium and higher serum intact parathyroid hormone levels. However, there was no significant difference between the groups in the cardiovascular event rate (OR: 0.58, 95% CI: 0.31-1.06, P=0.07) or in serum phosphorus levels. Conclusion: Compared with standard therapy, LC reduced all-cause mortality in patients on hemodialysis but did not decrease the risk of cardiovascular events. The decrease in serum phosphorus level was similar between LC and the other phosphate binders, but the risk of hypercalcemia was lower in patients who received LC. 
546 |a EN 
690 |a Lanthanum carbonate 
690 |a Hyperphosphatemia 
690 |a Hemodialysis 
690 |a All-cause mortality 
690 |a Dermatology 
690 |a RL1-803 
690 |a Diseases of the circulatory (Cardiovascular) system 
690 |a RC666-701 
690 |a Diseases of the genitourinary system. Urology 
690 |a RC870-923 
655 7 |a article  |2 local 
786 0 |n Kidney & Blood Pressure Research, Vol 43, Iss 2, Pp 536-544 (2018) 
787 0 |n https://www.karger.com/Article/FullText/488700 
787 0 |n https://doaj.org/toc/1420-4096 
787 0 |n https://doaj.org/toc/1423-0143 
856 4 1 |u https://doaj.org/article/fa2f3fef4ca64aa7a84f2283594c55a5  |z Connect to this object online.